About Ipamorelin MD

What this site is

Ipamorelin MD is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "MD" in the name is editorial framing — a position this publisher takes toward the literature, reading it with a clinical eye and leading with the skeletal evidence. It is not a claim that the site is a medical doctor, a medical practice, or a source of treatment, consultation, or prescriptions. There is no physician here, and there is no patient relationship of any kind.

How we handle the evidence

Every quantitative claim on this site — every dose, percentage, half-life, and effect size — is tied to a numbered citation in our Ipamorelin references. We describe what was administered to which species, at which dose, by which route, and we keep human and animal findings clearly separated. The bone-skeletal data lead this digest because they are the most quantitative part of the record, but we are explicit that they are preclinical.

We also keep two categories apart on purpose. Findings from controlled studies are cited and attributed. Effects described by the research-use community are clearly labeled anecdotal and are never presented as proven. We do not provide human dosing recommendations, and we do not tell anyone what to take.

What we don't do

We do not recommend ipamorelin, endorse its use, or suggest a protocol. We do not sell it or link to anyone who does. We do not use brand names for other compounds; we use generic scientific names only. And we do not overclaim: where the human evidence is thin or negative — as it is for ipamorelin, whose one Phase 2 trial missed its endpoint — we say so plainly. Our aim is a faithful, readable digest of what the studies measured, with the gaps named as carefully as the findings.